Agoracom Blog Home

Posts Tagged ‘Covid Testing’

Datametrex $DM.ca $DTMXF Announces OTCQB Listing $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-AB at 10:54 AM on Monday, April 19th, 2021
Datametrex ai logo 500x172 400 138
  • Company’s common shares will begin trading on the OTCQB® Venture Market (“OTCQB”) today, April 19, 2021 under the current stock symbol “DTMXF”
  • Marshall Gunter, CEO of Datametrex AI Limited, “With the Company’s shares now quoted on the OTCQB, it will enhance our visibility and make the Company’s shares available to a much larger group of U.S. investors. “

Toronto, Ontario–(Newsfile Corp. – April 19, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that after a successful application process for the OTCQB® Venture Market (“OTCQB”), the Company’s common shares will begin trading on the OTCQB today, April 19, 2021, at the opening of the market under the current stock symbol “DTMXF” and will remain listed on the TSX Venture Exchange under the ticker symbol “DM”.

Existing U.S. shareholders of Datametrex AI Limited shares, previously quoted on the OTC® Pink Open Market, will now be quoted on the OTCQB without any further action needed.

Marshall Gunter, CEO of Datametrex AI Limited, “With the Company’s shares now quoted on the OTCQB, it will enhance our visibility and make the Company’s shares available to a much larger group of U.S. investors. The quotation on the OTCQB is anticipated to enhance liquidity by providing current and prospective investors with an easily accessible and transparent trading platform where they go and obtain Real Time quotes and market information.”

About OTCQB

The OTCQB® Venture Market is the premier marketplace for entrepreneurial and development stage US and international companies that are committed to providing a high-quality trading and information experience for their US investors. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. The ability to have the Company’s shares electronically transferred between brokerages in the US is significantly more convenient and reduces the costs incurred in trading shares. When shares are able to trade electronically, existing investors benefit from greater liquidity and execution speeds, while opening the door to new investors that may have been previously restricted from the Company’s shares.

To read more, click here.

Datametrex $DM.ca Secures Authorization by Health Canada for PCL COVID19 Rapid Antigen Test Kit $DTMXF $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-AB at 1:58 PM on Tuesday, March 23rd, 2021
Datametrex ai logo 500x172 400 138

*PCL Antigen has a test sensitivity of 94.29% and the test kits are suitable for point of care tests. No extra equipment is needed.

*They are simple to use, and results are available in 10 minutes. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

Toronto, Ontario–(Newsfile Corp. – March 23, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that Heath Canada (“HC”) has approved the PCL Inc.’s (“PCL”) COVID19 AG Rapid test kit (“PCL Antigen”), an antigen point-of-care rapid test device under the Interim Order (“IO”) Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19. Datametrex made an application for the PCL Antigen under IO on August 24, 2020, Respecting the Importation and Sale of Medical Devices for use in relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act. (link: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/authorized/list.html)

According to the manufacturer, PCL Antigen has a test sensitivity of 94.29% and the test kits are suitable for point of care tests. No extra equipment is needed. They are simple to use, and results are available in 10 minutes. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

View the PCL Antigen test manual video by clicking the link: PCL COVID-19 ANTIBODY TEST

The following certifications have been awarded to these PCL Antigen test kits: CE Certificate, Korea KPMG, FIND Listed, UNGM Supplier. Countries includes the EU, 2 countries in the Middle East, Qatar and UAE, India, Russia, 3 countries in Latin America, Guatemala, Ecuador, and Colombia.

“Datametrex has been given another incredible opportunity to sell an additional medical testing device in Canada with the antigen test, with a supplier with outstanding medical devices in PCL. With the highly contagious new variant, and the second wave and possible third wave of COVID-19 in Canada and throughout the world, Datametrex believes an increase in testing capacity is critical to test and protect people,” said Marshall Gunter, CEO of Datametrex AI Limited.

The Company’s ability to fulfill any purchase order for the PCL Rapid test kits is subject to the availability of inventory at the time of order. Due to the extraordinarily high demand for COVID-19 test, there is volatility in the supply chain and available supply may fluctuate on a daily basis. Datametrex anticipates that it will have little, or no upfront costs associated with importing and selling these test kits.

To read more, click here.

Datametrex $DM.ca $DTMXF Announces Closing of Acquisition with Concierge Medical $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:38 AM on Thursday, February 11th, 2021
  • Closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).
  • Concierge is an arm’s length private telehealth and medical concierge services

Toronto, Ontario–(February 11, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex) is pleased to announce that further to its press releases dated January 7, 2021 and January 22, 2021, it has closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).

Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.

Terms of the Transaction

Pursuant to the Definitive Agreement, the Company issued 4,411,764 common shares in the capital of the Company (the “Common Shares“) to the Concierge Shareholders at a price of $0.17 per Common Share for an aggregate purchase price of $750,000.

No finder’s fee was payable in connection with the Transaction.

“Hospital ER’s and health practitioners’ clinics are making a strong push for patients who have mild symptoms to use telehealth platforms during the pandemic crisis to help alleviate the strain on emergency rooms and doctors’ offices and I believe this will continue after the pandemic crisis is over,” commented Dr. Jibran Sharif, MD, founder, and CEO of Concierge.

“Telemedicine visits are booming as doctors and patients have adopted social distancing amid the coronavirus crisis, and with the concierge services Dr. Sharif provide, we envision an end to end turnkey solution for patient healthcare,” said Marshall Gunter, CEO of Datametrex, with respect to the closing of the Transaction.

Operations of Concierge Upon Completion of the Transaction

Concierge has become a wholly-owned operating subsidiary of the Company. The Company has appointed Andrew Ryu, Marshall Gunter, and Dr. Jibran Sharif as the new board of the directors of Concierge, and Dr. Sharif is appointed as the President of Concierge following the closing of the Transaction (the “Closing“). In addition, concurrent with the Closing, the Company has entered into a employment agreement with the founder and President of Concierge, Dr. Jibran Sharif. In addition to his role as President of Concierge, Dr. Jibran Sharif will become the Chief Medical Officer of Datametrex.

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/755157-datametrex-announces-closing-of-acquisition-with-concierge-medical/messages/2303196#message

Victory Square Technologies $VST.ca $VSQTF Announces Completion of Acquisition of IV Hydreight, An On-Demand & On-Site Mobile Health, Pharmaceutical & Wellness Service Provider Across the USA $DBO.ca $NTAR.ca $SEV.ca $YDX.ca

Posted by AGORACOM-AB at 9:59 AM on Thursday, February 4th, 2021
  • Hydreight is a U.S.-based mobile health and wellness service provider
  • The firm leverages decentralized healthcare to bring quality telehealth to the masses in an efficient, scalable and cost effective way
  • The acquisition is expected to close tomorrow

Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides investors access to a diverse portfolio of next generation companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that it has executed a binding share purchase agreement (the “SPA”) dated January 29, 2021 with the shareholders of IV Hydreight Inc. (“Hydreight”), a mobile health and wellness service provider operating in the United States, pursuant to a share purchase agreement to acquire all of the shares of Hydreight (the “Acquisition”). Closing of the Acquisition is expected to occur on or about February 5, 2021.

Founded in 2018, Hydreight provides a unique, custom built, proprietary telemedicine service that allows users to book confidential health & wellness and/or medical services at their home, hotel, office or wherever they may need discreet assistance.

The business model of Hydreight leverages decentralized healthcare to bring quality telehealth, medical, health and wellness services to the masses in an efficient, scalable and cost effective way.

Hydreight Highlights

  • Hydreight provides a completely compliant turnkey business model for health professionals to offer fully licensed medical, health & wellness services through an on-demand and on-site platform.
  • Hydreight’s proprietary technology, mobile compliant medical inventory and integrated HIPPA compliant management tools make it the gold standard for USA state-certified mobile medicine protocols.
  • In addition to providing telehealth services, Hydreight also provides a diverse suite of health & wellness protocols that include IV drip, Botox, COVID-19 testing, and other medical and medispa treatments.

Read More: https://agoracom.com/ir/VictorySquareTechnologies/forums/discussion/topics/754637-victory-square-technologies-announces-completion-of-acquisition-of-iv-hydreight-an-on-demand-on-site-mobile-health-pharmaceutical-wellness-servi/messages/2301973#message

Datametrex AI $DM.ca $DTMXF Tracks Social Media Data to Understand “Reddit” Effect $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 8:16 AM on Thursday, February 4th, 2021
  • Announced that NexaSMART allows for deepened analysis and understanding of social media influence over stock prices.
  • Nexalogy will soon add Reddit and other data sources in order to expand AI interpretation of such trends.
  • NexaSMART stands for “Social Media Automated Reporting Technology.”

Toronto, Ontario–(February 4, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that NexaSMART allows for deepened analysis and understanding of social media influence over stock prices. Nexalogy will soon add Reddit and other data sources in order to expand AI interpretation of such trends. NexaSMART stands for “Social Media Automated Reporting Technology.”

Many investor eyes have turned to the subject of discussion forums such as Reddit that can have impact on the stock market and the price rise of specific stocks, sometimes even despite poor business indicators. According to the Wall Street Journal, mainstream journalists have linked cryptocurrency, stock speculation and conspiracy theories together as a formula for volatility in markets.1

In todays environment, investors rely even more on their investments to secure a comfortable retirement. We believe it is vital for people to know what the truth is and what is fiction when searching for information online that can have a major impact on their returns.

Nexalogy, the wholly owned subsidiary of Datametrex AI Limited, has expertise in disinformation research, and is able to track phenomenon of this nature as evidenced in NexaSMART reports (Read Report Here).

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/754635-datametrex-ai-tracks-social-media-data-to-understand-reddit-effect/messages/2301971#message

Datametrex $DM.ca $DTMXF Announces Investor Webinar $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 1:52 PM on Wednesday, February 3rd, 2021

Toronto, Ontario–(February 3, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that senior management will be hosting an investor update webinar on Tuesday, February 9, 2021, at 1:30 p.m. EST for a corporate update on the latest developments of the Artificial Intelligence technologies and COVID-19 test kits.

Webinar Details:

Date: Tuesday, February 9, 2021

Time: 1:30 p.m. ET

Registration Link: https://us02web.zoom.us/webinar/register/WN_Ge6setHBRAyeBLbKaUIUHQ

Datametrex plans to answer questions previously sent to [email protected] and during the webinar, at management’s discretion and subject to time constraints.

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/754580-datametrex-announces-investor-webinar/messages/2301880#message

Datametrex $DM.ca $DTMXF Secures Exclusive Rights to Distribute FDA, EUA and CE Approved #COVID-19 Saliva Kit $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 8:02 AM on Wednesday, February 3rd, 2021
  • Secured exclusive rights to sell and distribute COVID-19 saliva kit manufactured by WIZCHEM CO., LTD. in Canada and Saudi Arabia, and non-exclusive rights for the United States of America, United Kingdom, and European Unions.
  • COVICHEK™ Saliva Kit is a convenient DNA and RNA saliva collection device that stabilizes DNA and RNA long term in saliva sample. The saliva collection tube clearly indicates the volume of saliva required after which the funnel is removed, and cap replaced.

Toronto, Ontario–(February 3, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that it has secured exclusive rights to sell and distribute COVID-19 saliva kit manufactured by WIZCHEM CO., LTD. (“WIZCHEM”) in Canada and Saudi Arabia, and non-exclusive rights for the United States of America, United Kingdom, and European Unions.

The Company signed the distribution agreement on January 28, 2021, to sell the COVICHEK™ Saliva DNA/RNA Collection Kit and COVICHEK™ Viral Transport Medium (together “COVICHEK™”) in Canada, United States, European Union, United Kingdom, and the Kingdom of Saud Arabia. The Company did not pay any consideration to the manufacturer to obtain sales rights.

COVICHEK™ Saliva Kit is a convenient DNA and RNA saliva collection device that stabilizes DNA and RNA long term in saliva sample. The saliva collection tube clearly indicates the volume of saliva required after which the funnel is removed, and cap replaced. The device is fully specified for sample transport and storage.

WIZCHEM has secured U.S. FDA EUA, CE mark certification, and is Good Manufacturing Practice (GMP) facilities compliant. These tests are manufactured the with permission from the Korean FDA based on ISO 13485, and sold globally. Each of the manufacturers’ medical devices will be submitted to Health Canada (“HC”) for approval on a fast track basis and, until such approval is granted, these tests may not be sold or used in Canada at this time.

Read more: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/754512-datametrex-secures-exclusive-rights-to-distribute-fda-eua-and-ce-approved-covid-19-saliva-kit/messages/2301764#message

Datametrex $DM.ca $DTMXF Provides Update on #Ronin #Blockchain $HUT.ca $BITF.ca $GLXY.ca $HIVE.ca $VYGR.ca

Posted by AGORACOM-JC at 8:08 AM on Tuesday, February 2nd, 2021
  • As a result of favourable cryptocurrency market, the Company has determined that it would be in the best interest of all stakeholders of Datametrex to reactivate Ronin by spinning off and raising funds directly into Ronin.

Toronto, Ontario–(February 2, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”)  is pleased to announce today that the board has completed its strategic review of Ronin Blockchain Corp. (“Ronin”).

As a result of favourable cryptocurrency market, the Company has determined that it would be in the best interest of all stakeholders of Datametrex to reactivate Ronin by spinning off and raising funds directly into Ronin.

The above actions are subject to a number of approvals including the TSX Venture Exchange, plan of arrangement to spin the entity out to our shareholders, and potentially shareholders approval. Datametrex will continue to provide updates to the market as the process progresses including information about the structure of the financing and transaction.

Read more: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/754416-datametrex-provides-update-on-ronin/messages/2301559#message

Datametrex $DM.ca $DTMXF Announces Another COVID-19 Test Kit Sales to Canadian Mining Company $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:59 AM on Monday, February 1st, 2021
  • Received a Purchase Order from a Canadian mining company for COVID-19 test kits manufactured by 1drop Inc., and ancillary products.
  • The total gross sales amount of the sales is approximately $250,000 CAD, excluding shipping and courier fees.
  • This brings approximately $2.8M sales to date to the Canadian mining companies.

Toronto, Ontario–(February 1, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”), is pleased to announce that it has received a Purchase Order (the “PO”) from a Canadian mining company (the “Purchaser”) for COVID-19 test kits manufactured by 1drop Inc. (“1drop”), and ancillary products. The total gross sales amount of the sales is approximately $250,000 CAD, excluding shipping and courier fees. This brings approximately $2.8M sales to date to the Canadian mining companies.

Under the terms of the sale to the Purchaser, Datametrex will provide 1drop COVID-19 qPCR Detection Kits, a PCR machine, an RNA extraction machine, and RNA extraction kits. Datametrex anticipates that it has a little or no upfront costs associated with the sale of the test kits. All of the items are shipped directly from manufacturers to the purchaser’s mine operating sites.

“This further confirms Datametrex’s approach with its diverse COVID-19 product portfolio of health security products and services,” stated Marshall Gunter, CEO of Datametrex.

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/754315-datametrex-announces-another-covid-19-test-kit-sales-to-canadian-mining-company/messages/2301339#message

Datametrex $DM.ca $DTMXF Announces Definitive Agreement with Concierge Medical $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:51 AM on Friday, January 22nd, 2021
  • Announced that further to its press release dated January 7, 2021, it has entered into a share exchange agreement with Concierge Medical Consultants Inc. and the shareholders of Concierge effective January 19, 2021 to acquire 100% of Concierge’s issued and outstanding securities
  • Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.

Toronto, Ontario–(January 22, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex) is pleased to announce that further to its press release dated January 7, 2021, it has entered into a share exchange agreement with Concierge Medical Consultants Inc. (“Concierge“) and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“) to acquire 100% of Concierge’s issued and outstanding securities (the “Transaction“). Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.

“Health care is on the verge of a revolution, one that will be driven by A.I. technologies. Medical services are already strained by the growing demand for healthcare worldwide. By leveraging A.I. technologies, medical we will be able to provide services more quickly and accurately,” said Marshall Gunter, CEO of Datametrex.

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/753658-datametrex-announces-definitive-agreement-with-concierge-medical/messages/2299447#message